Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 28, 2014

View Archived Issues

Enanta Pharma CEO describes company outlook at J.P. Morgan Healthcare Conference

MAGED4 associated with progression of squamous cell carcinoma of the esophagus

Genentech and Xenon Pharmaceuticals patent novel sodium channel blockers

New monospecific HLA-E antibodies described by The Terasaki Family Foundation

Novel endothelial lipase inhibitors synthesized by Bristol-Myers Squibb

Takeda Pharmaceutical designs novel PI3Kdelta inhibitors

Korean researchers present new fusion proteins for diabetes

Immune Design treats first patient in phase I trial of IDG-100

Pfizer reports topline data from two phase III trials of dacomitinib in NSCLC

Sirona Biochem signs licensing agreement with Wanbang Biopharmaceuticals

DENND2D identified as a biomarker of esophageal cancer prognosis

Bristol-Myers Squibb reviews activity of fourth quarter 2013

Progen commences phase I trial of anticancer candidate in Australia

Enrollment completed in phase III trial of CTI's anticancer agent Opaxio

FOB Synthesis and AstraZeneca sign option and license agreement for novel antibiotics

Teva Pharmaceutical launches phase III trial of allogeneic MPCs in chronic heart failure

Adenovir Pharma initiates phase II study of antiviral drug for infectious eye disease

Metabolic Pharmaceuticals licenses AOD-9604 to Australian Custom Pharmaceuticals

Phase I trial to evaluate IGN-523 in acute myeloid leukemia

Celsion discloses new phase III overall survival data supporting continued development of ThermoDox

Neuren provides update on phase II trials of NNZ-2566 in four separate neurological disorders

Sosei transfers Japanese marketing authorization for emergency contraceptive to ASKA

Galectin Therapeutics and SBH Sciences form new venture to develop oral galectin inhibitors

Two-herb traditional Chinese medicine proves beneficial for diabetic foot ulcers

Specific PIPT inhibitors synthesized for interference with phosphoinositide signaling

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...